Navigation Links
Prostate cancer vaccines more effective with hormone therapy
Date:7/9/2008

PHILADELPHIA Among patients with castration-resistant prostate cancer, the addition of hormone therapy following vaccine treatment improved overall survival compared with either treatment alone or when the vaccine followed hormone treatment, according to recent data published in the July 15 Clinical Cancer Research, a journal of the American Association for Cancer Research.

Philip M. Arlen, M.D., director of the Clinical Research Group for the Laboratory of Tumor Immunology and Biology, Center for Cancer Research, at the National Cancer Institute, said the findings have important implications for guiding treatment decisions for prostate cancer patients.

"Vaccines, if and when they are approved, can be safely and effectively combined with other therapies, including hormones," said Arlen. "There appears to be an advantage in overall survival."

Arlen and colleagues enrolled 42 patients who had castration-resistant prostate cancer. These patients were randomly assigned to receive either a poxvirus-based prostate-specific antigen vaccine or hormone therapy with nilutamide. At progression, patients received the other therapy and continued to receive their original therapy.

For all the patients enrolled in the study, the three-year survival probability was 71 percent and the median overall survival was 4.4 years. Patients randomized to the vaccine had a three-year survival probability of 81 percent and an overall survival of 5.1 years, while patients taking nilutamide had a three-year survival probability of 62 percent and an overall survival of 3.4 years.

Of the 42 patients in the study, 12 patients who were originally assigned to vaccine switched to nilutamide plus vaccine and eight patients who were originally assigned to nilutamide switched to vaccine plus hormone, due to rising levels of prostate-specific antigen with no evidence of metastasis. For patients who received vaccine and then nilutamide, the three-ye
'/>"/>

Contact: Jeremy Moore
Jeremy.moore@aacr.org
267-646-0557
American Association for Cancer Research
Source:Eurekalert

Page: 1 2

Related biology news :

1. Counting tumor cells in blood predicts treatment benefit in prostate cancer
2. Urologists identify 7 biomarkers that may help pinpoint prostate cancer recurrence
3. Certain form of tomatoes could be key to prostate cancer prevention
4. Estrogen helps drive distinct, aggressive form of prostate cancer
5. Genes may play role in risk assessment for prostate cancer among Hispanics and caucasians
6. Biomarker predicts malignancy potential of HG-PIN lesions in the prostate
7. Potential association of type 2 diabetes genes with prostate cancer
8. New, noninvasive prostate cancer test beats PSA in detecting prostate cancer
9. Prostate cancer: Watchful wait or vaccinate?
10. Nanomedicine research for prostate cancer supported by $5 million gift
11. Safeway Inc. and PCF to fund landmark prostate cancer research collaboration

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/4/2009)... What,s the cost of saving a teena...ath resulting from prescription medication abuse, ..., however, may be unaware that the lock-boxes they...the ticking timebomb of prescription drugs. That,s...ity medical supplies, has formed an exclusive part...
(Date:11/4/2009)...ntists at the University of North Carolina at Chap...alifornia, San Francisco have developed and experi...diseases for existing drugs. , The researchers d...similar the structures of all known drugs are to t...s ligands -- of disease targets within the cell. I...
(Date:11/3/2009)...ember 4, 2009) For more than 25 years, all attemp...mbus gigas ) have been unsuccessfuluntil now. For ...niques to produce beaded (nucleated) and non-beade...eveloped by scientists from Florida Atlantic Unive...I). With less than two years of research and exper...
Breaking Biology News(10 mins):MEDNET Launches MedSafe to Prevent Teenage Prescription Drug Abuse 2MEDNET Launches MedSafe to Prevent Teenage Prescription Drug Abuse 3Study points to new uses, unexpected side effects of already existing drugs 2Scientists are first to 'unlock' the mystery of creating cultured pearls from the queen conch 2Scientists are first to 'unlock' the mystery of creating cultured pearls from the queen conch 3Anadys Pharmaceuticals Inc Announces Strategic Restructuring to Focus Operations on Continuing the Advancement of ANA598 12473 1Anadys Pharmaceuticals Inc Announces Strategic Restructuring to Focus Operations on Continuing the Advancement of ANA598 12473 2Anadys Pharmaceuticals Inc Announces Strategic Restructuring to Focus Operations on Continuing the Advancement of ANA598 12473 3Anadys Pharmaceuticals Inc Announces Strategic Restructuring to Focus Operations on Continuing the Advancement of ANA598 12473 4Anadys Pharmaceuticals Inc Announces Strategic Restructuring to Focus Operations on Continuing the Advancement of ANA598 12473 5Jefferson researchers identify critical marker of response to gemcitabine in pancreatic cancer 47918 1Jefferson researchers identify critical marker of response to gemcitabine in pancreatic cancer 47918 2Scientists discover new genetic immune disorder in children 8716 1Scientists discover new genetic immune disorder in children 8716 2Scientists discover new genetic immune disorder in children 8716 3
... have discovered the first microRNAs tiny bits of...of 10 major degenerative muscular disorders, openi... understanding of these debilitating, poorly under...e published online this week by the Proceedings of... Eisenberg, PhD, of the Program in Genomics at Chi...
... October 17, 2007A late-breaking symposium, Colony...tus, Potential Causes, and Preventive Measures, ha...f the Entomological Society of America (ESA), to b... headed by entomologists Diana Cox-Foster (Penn St...xplore possible factors that may have caused honey...
...n, DC. Ocean Conservancy Scientist, Wallace J. Nic...rcher Hoyt Peckham found surprising results in a r...at Nichols and Peckham conducted over the course o...tober 17 in the online, open-access journal PLoS O... operations are a greater threat to the survival o...
Other Biology News:Massive microRNA scan uncovers leads to treating muscle degeneration 2Research shows loggerhead sea turtles threatened by small-scale fishing operations 2
(Date:11/5/2009)...swire-FirstCall/ -- GenVec, Inc. (Nasdaq: GNVC ) ...d quarter ended September 30, 2009. GenVec reporte... the three months ended September 30, 2009 compare...in the comparable quarter of 2008. For the nine mo...as $14.1 million ($0.15 per share), compared to a ...
(Date:11/5/2009)...ember 5, 2009 at 4:30 p.m. Eastern Time , BOT...l/ - OncoGenex Pharmaceuticals, Inc. ("OncoGenex" ...unaudited financial results for the third quarter ...wed the Company,s highlights for the third quarter... reflect the operations of OncoGenex Technologies ...
(Date:11/5/2009)... Senomyx, Inc. (Nasdaq: ...te receptor-based technologies to discover novel f...edient supply industries, today provided a corpora...hird quarter ended September 30, 2009. Revenues w...mpared to $4.0 million for the third quarter of 20...
(Date:11/5/2009)...y and vision correction experts listed in the Trus...d at the recently concluded American Academy of Op...isco, California. Dr. Stephen Brint, MD, Dr. Frede...r. Peter Rapoza, MD, Dr. Michael Raizman, MD, Dr. ...dward Manche, MD, and Dr. Parag Majmudar, MD, all ...
Breaking Biology Technology:GenVec Reports Third Quarter 2009 Financial Results 2GenVec Reports Third Quarter 2009 Financial Results 3GenVec Reports Third Quarter 2009 Financial Results 4GenVec Reports Third Quarter 2009 Financial Results 5GenVec Reports Third Quarter 2009 Financial Results 6OncoGenex Reports Third Quarter 2009 Financial Results 2OncoGenex Reports Third Quarter 2009 Financial Results 3OncoGenex Reports Third Quarter 2009 Financial Results 4OncoGenex Reports Third Quarter 2009 Financial Results 5OncoGenex Reports Third Quarter 2009 Financial Results 6OncoGenex Reports Third Quarter 2009 Financial Results 7OncoGenex Reports Third Quarter 2009 Financial Results 8SENOMYX ANNOUNCES CORPORATE UPDATE AND THIRD QUARTER 2009 FINANCIAL RESULTS 2SENOMYX ANNOUNCES CORPORATE UPDATE AND THIRD QUARTER 2009 FINANCIAL RESULTS 3SENOMYX ANNOUNCES CORPORATE UPDATE AND THIRD QUARTER 2009 FINANCIAL RESULTS 4SENOMYX ANNOUNCES CORPORATE UPDATE AND THIRD QUARTER 2009 FINANCIAL RESULTS 5SENOMYX ANNOUNCES CORPORATE UPDATE AND THIRD QUARTER 2009 FINANCIAL RESULTS 6SENOMYX ANNOUNCES CORPORATE UPDATE AND THIRD QUARTER 2009 FINANCIAL RESULTS 7SENOMYX ANNOUNCES CORPORATE UPDATE AND THIRD QUARTER 2009 FINANCIAL RESULTS 8SENOMYX ANNOUNCES CORPORATE UPDATE AND THIRD QUARTER 2009 FINANCIAL RESULTS 9SENOMYX ANNOUNCES CORPORATE UPDATE AND THIRD QUARTER 2009 FINANCIAL RESULTS 10SENOMYX ANNOUNCES CORPORATE UPDATE AND THIRD QUARTER 2009 FINANCIAL RESULTS 11SENOMYX ANNOUNCES CORPORATE UPDATE AND THIRD QUARTER 2009 FINANCIAL RESULTS 12SENOMYX ANNOUNCES CORPORATE UPDATE AND THIRD QUARTER 2009 FINANCIAL RESULTS 13SENOMYX ANNOUNCES CORPORATE UPDATE AND THIRD QUARTER 2009 FINANCIAL RESULTS 14Leading Vision Correction Experts in Trusted LASIK Surgeons Directory Educate Fellow Doctors at AAO Annual Meeting 2Leading Vision Correction Experts in Trusted LASIK Surgeons Directory Educate Fellow Doctors at AAO Annual Meeting 3Leading Vision Correction Experts in Trusted LASIK Surgeons Directory Educate Fellow Doctors at AAO Annual Meeting 4Leading Vision Correction Experts in Trusted LASIK Surgeons Directory Educate Fellow Doctors at AAO Annual Meeting 5Leading Vision Correction Experts in Trusted LASIK Surgeons Directory Educate Fellow Doctors at AAO Annual Meeting 6Leading Vision Correction Experts in Trusted LASIK Surgeons Directory Educate Fellow Doctors at AAO Annual Meeting 7Leading Vision Correction Experts in Trusted LASIK Surgeons Directory Educate Fellow Doctors at AAO Annual Meeting 8Leading Vision Correction Experts in Trusted LASIK Surgeons Directory Educate Fellow Doctors at AAO Annual Meeting 9
...alif., Sept. 18 InterMune, Inc.,(Nasdaq: ITMN ) ... market,and other conditions, 3,000,000 shares of ...g. The Company expects to grant the underwriters,a...,000 shares of common,stock in connection with the...be sold by InterMune. Goldman, Sachs & Co. is act...
...alif., Sept. 18 Dynavax,Technologies Corporation ...Vice President and Chief Financial Officer, will p...Global Life Sciences Conference in New York, New,Y...n Daylight Savings Time,(6:30 a.m. PDST). The pres...o broadcast and the subsequent archived audio,reco...
...as, Sept. 18 Luminex Corporation,(Nasdaq: LMNX )...he fourth,annual America,s Growth Capital Emerging...in Boston. The investor presentation by Patrick J... and Harriss T. Currie, chief financial officer, w...eptember 20, 2007. The,presentation will be webcas...
Other Biology Technology:InterMune Announces Proposed Public Offering of Common Stock 2Dynavax to Present at UBS 2007 Global Life Sciences Conference 2Luminex Corporation to Present at America's Growth Capital Emerging Growth Conference 2
Anti-IL-12 / IL-23 Monoclonal Antibody, Alexa Fluor 647 Conjugated, Clone C17.8 from eBioscience
Rabbit Anti-Human Naked1 Polyclonal Antibody, Unconjugated from Cell Signaling Technology
Rabbit Anti-Phosphothreonine-X-Phosphotyrosine Polyclonal Antibody, Horseradish Peroxidase Conjugated from Abcam
Rabbit Anti-Human ADAMTS-4, disintegrin-like domain Antibody, Unconjugated from CHEMICON
Biology Products: